Boston Scientific Announces Additions to Clinical Sciences Organization
26 Octubre 2007 - 4:00PM
PR Newswire (US)
Dr. Keith Dawkins and Dr. Takahiro Uchida to join the Company
NATICK, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Boston Scientific
today announced that Keith Dawkins, M.D., and Takahiro Uchida,
M.D., will be joining the Company's Clinical Sciences organization.
Dr. Dawkins will serve as Senior Vice President and Associate Chief
Medical Officer, sitting on both the Clinical Leadership team and
the Company's Operating Committee. He is an internationally known
senior interventional cardiologist at Southampton University
Hospital in England, and a former President of the British
Cardiovascular Society. He trained in medicine at London University
(Guy's Hospital), and in cardiology at the Brompton Hospital
(London), John Radcliffe Hospital (Oxford), and Stanford University
Medical Center. He has served as an advisor to the Department of
Health in the United Kingdom, and he has worked closely with a
number of regulatory agencies there, including the Medicines and
Healthcare Products Regulatory Agency (MHRA) and the National
Institute for Clinical Excellence (NICE). He will be responsible
for leading the medical input process for the Company's
Interventional Cardiology, Peripheral Intervention and
Neurovascular businesses. He will also participate in the
formulation and execution of technology strategies for both
internal research and development, as well as business development
activities. In addition, he will oversee development and
dissemination of scientifically based education materials to inform
customers and regulators. "We are delighted to have Dr. Dawkins
joining us," said Donald S. Baim, M.D., Boston Scientific's Chief
Medical and Scientific Officer. "He is a well-published scientific
contributor who has been actively involved in the development of
the TAXUS(R) Stent System. He is also a respected medical lecturer
who is universally recognized for his keen insights into a broad
variety of cardiology and cardiology device-related issues. The
addition of Dr. Dawkins will greatly enhance the capabilities of
the Clinical Sciences organization at Boston Scientific." Dr.
Dawkins will join the Company in January. Dr. Takahiro Uchida, who
will serve as a Director in Clinical Research and as Medical
Director, International, is another key addition to the Clinical
Sciences organization. He is a skilled interventional cardiologist
who received his Medical Degree from Fukushima Medical University,
followed by an M.S. in Epidemiology from the Harvard School of
Public Health, and a Doctor of Philosophy in Medicine from Tokyo
Women's Medical University. After training with the Japanese
Pharmaceuticals and Medical Devices Agency (PMDA), Dr. Uchida
became a research fellow in the Division of Clinical Biometrics at
the Brigham and Women's Hospital and the Harvard Clinical Research
Institute. Most recently, Dr. Uchida has served as a Medical
Officer in the Interventional Cardiovascular Device Branch of the
Center for Devices and Radiological Health (CDRH) of the U.S. Food
and Drug Administration. He will be responsible for providing
high-level medical input on the design, regulatory strategy and
conduct of a broad range of international trials concentrated in
the cardiovascular area, while also providing a strong
communication link to the key regulatory bodies and customer base
worldwide. "Dr. Uchida will play an important role on our global
Clinical Sciences team," said Dr. Baim. "He is well qualified for
his important new role by virtue of his training as an
interventional cardiologist, uniquely augmented by his experience
with clinical trials from both the biostatistical trial conduct and
regulatory perspectives, through his service with the Japanese and
U.S. regulatory agencies." Dr. Uchida will join the Company in
December. "The addition of these two highly capable individuals
significantly strengthens Boston Scientific's Clinical Sciences'
capabilities, and further enhances our ability to serve as the
'voice of the patient' by providing the highest-level expert
clinical input throughout the product life cycle of our current and
future medical devices," added Dr. Baim. "Combined with the talents
of nearly 400 other professionals within our group, the unique
skills and contributions of Dr. Dawkins and Dr. Uchida will be
invaluable in helping us maintain and expand Boston Scientific's
worldwide leadership in the treatment of cardiovascular disease and
the broad range of other life- threatening and disabling diseases."
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more information,
please visit: http://www.bostonscientific.com/. Cautionary
Statement Regarding Forward Looking Statements This press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect,"
"project," "believe," "plan," "estimate," "intend" and similar
words. These forward- looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding clinical science, product performance
and competitive offerings. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.
These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements. Factors
that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property;
litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A- Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors
in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly
update or revise any forward- looking statements to reflect any
change in our expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document. CONTACT: Paul Donovan 508-650-8541 (office)
508-667-5165 (mobile) Media Relations Boston Scientific Corporation
Dan Brennan 508-650-8538 (office) 617-459-2703 (mobile) Investor
Relations Boston Scientific Corporation DATASOURCE: Boston
Scientific Corporation CONTACT: Paul Donovan, Media Relations,
+1-508-650-8541 (office), +1-508-667-5165 (mobile) or Dan Brennan,
Investor Relations, +1-508-650-8538 (office), +1-617-459-2703
(mobile), both of Boston Scientific Corporation Web site:
http://www.bostonscientific.com/
Copyright